藥物短缺更新與新療法核准資訊
Updates on medication shortages and new therapeutic approvals
Updated at: September 4, 2026 at 03:45 AM
截至2026年年中，美國製藥業呈現出一個驚人的矛盾。
As of mid-2026, the U.S. pharmaceutical landscape presents a striking paradox.
儘管美國食品藥品監督管理局(FDA)在創新藥物審批方面持續取得突破（包括針對多發性骨髓瘤的救命療法以及先進的愛滋病病毒(HIV)治療方案），但醫療體系在基本藥物供應方面正面臨持續的危機。
While the FDA continues to break ground with innovative approvals—including life-saving treatments for multiple myeloma and advanced HIV therapies—the healthcare system faces a persistent crisis in the availability of essential medications.
目前活性藥物短缺的數量已攀升至227種，許多關鍵藥物，例如學名藥無菌注射劑和腫瘤治療藥物，變得越來越難以獲取。
The number of active drug shortages has climbed to 227, with many critical drugs, such as generic sterile injectables and oncology treatments, becoming increasingly difficult to secure.
這種脆弱性的根源在於市場過度集中，近一半的新短缺病例涉及單一來源產品，加上抑制學名藥生產的經濟壓力。
This fragility is rooted in market concentration, where nearly half of new shortages involve sole-source products, alongside economic pressures that discourage generic production.
因此，臨床團隊往往被迫依賴次優的替代療法，這會導致治療延誤和錯誤的風險。
Consequently, clinical teams are often forced to rely on suboptimal substitutions, which risks treatment delays and errors.
儘管存在這些營運障礙，業界仍抱持希望，因為新療法正聚焦於罕見疾病和口服給藥，反映出向更專業化護理的轉型。
Despite these operational hurdles, the industry remains hopeful as new therapies focus on rare diseases and oral administration, reflecting a transition toward more specialized care.
